04.02.24 -- How Pharma 4.0 Can Unlock The Full Potential Of External Manufacturing

Learn how following strict laboratory practices and routine Mycoplasma contamination testing using nucleic acid-based assays can help ensure safe and high-quality biopharmaceutical production.

Increased demand for protein delivery and the emergence of advanced modalities — including mRNA — are introducing new challenges to the development life cycle, such as high-concentration formulations.

The key to a biopharma executive's success is making the right decisions at the right time. Which will get your biologic to the clinic quickly and cost-effectively, without compromising quality and patient safety?

Ensuring optimal yield for engineered viral vectors early in a process is crucial to ensuring their eventual commercial viability and broader patient accessibility.

Explore how overcoming inherent challenges in design, conjugation, and production is paving the way for continued advancement and personalized ADC-based treatment regimens.

Dive into the necessary components of a smooth tech transfer for LNP-based drugs, including the variables that impact LNP formulation and the outsourcing strategies needed to avoid common pitfalls.

Learn about three biosafety testing methods that are commonly applied: in vitro adventitious virus (IVV), species-specific virus testing such as minute virus of mice (MVM), and mycoplasma.